/
Cardiovascular
Ischemic Stroke
108
Pipeline Programs↗
242
Active Trials↗
91
Companies Involved↗
Ischemic stroke is a highly competitive landscape with 108 programs across 91 companies. The most active players are Shin Poong Pharmaceutical Co. Ltd., Basking Biosciences, Inc., Shaanxi Micot Pharmaceutical Technology Co., Ltd.. 29 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
SPhase 3BPhase 2SPhase 2HPhase 1PPreclinical
Preclinical
Shin Poong Pharmaceutical Co. Ltd.
1 program
Basking Biosciences, Inc.
1 program
Shaanxi Micot Pharmaceutical Technology Co., Ltd.
1 program
Hopstem Biotechnology Inc.
1 program
POLYSAN Scientific & Technological Pharmaceutical Company
1 program
Astellas
1 program
Pipeline
Programs by Phase
Preclinical52
Phase 15
Phase 222
Phase 329
Approved
No programs
Analysis
Modality Breakdown
82%
Small molecule
79 of 96 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 96 classified programs, each share of the total. Modality classified for 97% of 108 pipeline programs.
Analysis
Trial Status
647
clinical trials
Completed231 · 36%
Recruiting143 · 22%
Unknown status106 · 16%
Not yet recruiting80 · 12%
Terminated43 · 7%
Withdrawn19 · 3%
Other25 · 4%
Clinical Trials
Trial Activity
647 trials
Rescue Endovascular Treatment After Neurological Deterioration in Initially Mild Basilar Artery Occlusion in an Extended Time Window
Recruiting·FFirst Affiliated Hospital of Wannan Medical College·Preclinical·NCT06843356·159 enrolled
Improving Neuroprotective Strategy for Ischemic Stroke With Poor Recanalization After Thrombectomy by Intra-arterial TNK (INSIST-TNK): a Prospective, Single Arm, Pilot Study
Recruiting·—·Preclinical·NCT04201964·30 enrolled
Intra-arterial Neuroprotective Strategy for Ischemic STroke Patients With No Reperfusion Therapy (INSIST-NRT): One Single Center, Safety and Feasibility Study
Recruiting·—·Preclinical·NCT04664946·30 enrolled
Page 1 of 44
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)